Table 8.
Comparison of LRR in pCR and non-pCR patients after BCS and mastectomy in different subtypes
| Parameters | Subtype | Recurrence patterns | Pathological total response | ||
|---|---|---|---|---|---|
| Operation type | pCR | Non-pCR | P value | ||
| (N = 91) | (N = 524) | ||||
| Mastectomy | HR + /HER2- | LRR | 1 (9.1%) | 25 (9.8%) | > 0.999 |
| (N = 615) | (N = 266) | No LRR | 10 (90.9%) | 230 (90.2%) | |
| HR + /HER2 + | LRR | 0 | 11 (10.8%) | 0.12 | |
| (N = 130) | No LRR | 28 (100%) | 91 (89.2%) | ||
| HR−/HER2 + | LRR | 1 (2.5%) | 15 (14.3%) | 0.071 | |
| (N = 145) | No LRR | 39 (97.5%) | 90 (85.7%) | ||
| HR−/HER2− | LRR | 2 (16.7%) | 11 (17.7%) | > 0.999 | |
| (N = 74) | No LRR | 10 (83.3%) | 51 (82.3%) | ||
| Conserving breast surgery | HR + /HER2− | LRR | 1 (6.3%) | 6 (4.4%) | 0.546 |
| (n = 432) | (N = 153) | No LRR | 15 (93.7%) | 131 (95.6%) | |
| HR + /HER2 + | LRR | 3 (7.9%) | 5 (7.2%) | > 0.999 | |
| (N = 107) | No LRR | 35 (92.1%) | 64 (92.8%) | ||
| HR−/HER2 + | LRR | 4 (8.3%) | 9 (25.0%) | 0.037 | |
| (N = 84) | No LRR | 44 (91.7%) | 27 (75.0%) | ||
| HR−/HER2− | LRR | 0 | 10 (20.4%) | 0.002 | |
| (N = 88) | No LRR | 39 (100%) | 39 (79.6%) | ||
HR hormone receptor, HER-2 human epidermal growth factor receptor 2, LRR locoregional recurrence, pCR pathological complete response